Is a universal vaccine against cancer possible?
A new study has presented a potential strategy for a universal human cancer vaccine. This article delves into the researchers’ findings, exploring their methodologies and results.
List view / Grid view
Articles
Antibody characterisation – an essential researchers’ resource
Central to reproducibility in biomedical research is the ability to use well-characterised and defined reagents. The CPTAC Antibody Portal serves as a National Cancer Institute community resource that provides access to many standardised renewable affinity reagents to cancer-associated targets and accompanying characterisation data. Nikki Withers spoke to Dr Tara Hiltke…
CRISPR: kick-starting the revolution in drug discovery
Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of…
Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
The implication of a dysfunctional proteasome regulator in neurodegenerative disease
Disrupted protein homeostasis from PI31 inactivation may initiate the process of neurodegeneration seen in Alzheimer’s, ALS and other similar diseases, says new research.
Using droplet digital PCR to monitor the safety of CAR T cells
CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR…
Championing genomics in the UK
Professor Sir John Bell, Regius Professor of Medicine at the University of Oxford, delivered a speech at the MHRA’s 14th Annual Lecture in London, outlining his vision for the UK life sciences industry. Here, Nikki Withers summarises the key take-home messages from the talk, including how UK researchers and investors…
Expert view: The future of cell expansion for monoclonal antibody production
There is room for improvement in the production of monoclonal antibodies; commercial production needs increased process efficiency and reduced costs.
Expert view – The Octet HTX system: enabling multi-purpose screening of therapeutic biologics during development
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
Expert view: Promising methods in kinase screening
Kinase-mediated phosphorylation is a control point for nearly all activity within a cell, making kinases important in many diseases.
Expert view: Following mitchondrial substrate oxidation pathways to expose novel drug targets
Energy metabolism drives everything we do, so it is no surprise that the more we discover about these metabolic processes, the more we observe seamless integration with all core cellular functions.
Five recent drug target discoveries for pancreatic cancer
This article highlights some of the most recent drug target discoveries that could be used to develop and design a treatment for pancreatic cancer.
Hit-To-Lead In-Depth Focus 2019
This in-depth focus features articles on identifying new leads for neglected tropical diseases and how to develop novel peptide hits into lead compounds.
Targets In-Depth Focus 2019
The articles in this In-Depth Focus explore a novel technique for studying protein aggregation in Alzheimer's research and explain how to maximise the potential of mass spectrometry.
Screening In-Depth Focus 2019
In this In-Depth Focus are articles investigating how CROs can help to drive innovation and how CRISPR technologies could be used for drug screening purposes.
